Piracetam

Piracetam (2-oxo-1-pyrrolidineacetamide, research code UCB 6215, trade name Nootropil) is a synthetic compound, a 2-pyrrolidinone ring with an acetamide group on its nitrogen, and the first racetam. A 2001 Lancet review traces it to Corneliu Giurgea's research in the late 1960s and credits him with coining the word "nootropic" (Shorvon, 2001). Most of the world's piracetam has been marketed by the Belgian company UCB (Flicker and Grimley Evans, 2001).

The two sources do not conflict.

Published piracetam research falls into six areas, each with its model stated below. Mechanism data come from cells, membranes and animals; the human trials are mostly older and small, with mixed findings.

Proposed mechanisms: membranes and AMPA receptors

The piracetam mechanism is not settled (Shorvon, 2001). In vitro, 0.1 to 1.0 mM piracetam raised the fluidity of brain membranes from aged mice, rats and humans but not from young mice; in rats given 300 mg/kg once daily, regional membrane fluidity and active avoidance learning rose in aged animals only (Müller et al., 1997).

In cultured cerebellar granule cells, micromolar piracetam raised AMPA-stimulated calcium influx, increasing efficacy rather than potency, and it raised AMPA binding site density in rat cortical membranes (Copani et al., 1992). In GluA2 and GluA3 crystal structures, piracetam sits at several low-occupancy sites along the interface between two subunits, while aniracetam binds one central site (Ahmed and Oswald, 2010). Models: brain membranes, neuron cultures, rats and receptor crystals.

Red cell deformability

Filtering oxygenated sickle cell (HbSS) red cells through polycarbonate microsieves showed that piracetam raised their deformability in vitro, and the authors reported a similar change in vivo after oral intake (Gini and Sonnet, 1987). A Cochrane review of three trials with 169 participants found insufficient reliable evidence to support routine use of piracetam for preventing painful sickle cell crises (Al Hajeri and Fedorowicz, 2016). Models: sickle red cells and human trials.

Rodent memory models

Rodent findings depend on age, genotype and task. Young male rats given 250 mg/kg chronically learned a spatial three-choice task faster, but they extinguished it more slowly and were impeded in reversal learning (Christoffersen et al., 1998). Male Ts65Dn mice, a Down syndrome model, and euploid mice received 0, 75, 150 or 300 mg/kg intraperitoneally each day, starting 4 weeks before Morris water maze testing.

Euploid mice at 75 and 150 mg/kg performed better on the visible and hidden platform tasks, but in Ts65Dn mice every amount prevented the usual gains across trials, and the authors wrote that the data do not support its use in Down syndrome (Moran et al., 2002). These are animal data only. Models: rats and mice.

Cortical myoclonus

The Lancet review notes piracetam's licensing for its antimyoclonic action and for effects after stroke and in mild cognitive impairment (Shorvon, 2001). In a double-blind, placebo-controlled crossover trial, 21 people with disabling myoclonus, all but one with electrophysiological signs of cortical origin and all chosen after apparent responses to piracetam, received 14 days of each, mostly alongside other antimyoclonic drugs.

Ten needed rescue from the placebo phase because their myoclonus worsened severely, none from the piracetam phase, and total rating scores differed significantly in favor of piracetam, by a median of 22 percent (Brown et al., 1993). In 20 people aged 17 to 43 with Unverricht-Lundborg disease, a progressive myoclonus epilepsy, a multicenter, randomized, double-blind crossover trial of placebo and two of three daily amounts found significant changes in the primary rating score at the highest amount (Koskiniemi et al., 1998). Model: human crossover trials.

Dementia and cognitive impairment reviews

A 2001 Cochrane review found that many trials were crossovers without usable first-phase data. Only global impression of change had enough pooled data; it favored piracetam (fixed-effects odds ratio 3.55, 95% CI 2.45 to 5.16, with heterogeneity), while effects on cognition and other measures were inconclusive, and the reviewers concluded that the published evidence does not support piracetam for dementia or cognitive impairment (Flicker and Grimley Evans, 2001).

A 2002 meta-analysis led by a UCB researcher pooled 19 double-blind, placebo-controlled studies in older adults with dementia or cognitive impairment and reported a significant odds ratio favoring piracetam on clinical global impression of change (Waegemans et al., 2002). A 2024 meta-analysis of 18 studies in 886 adults with memory impairment found no clear memory difference (standardized mean difference 0.75, 95% CI -0.19 to 1.69, I² 96%) (Gouhie et al., 2024). Model: meta-analyses of human trials.

Post-stroke aphasia and cerebral blood flow

In a double-blind trial in 24 people with aphasia after stroke, all given speech therapy, PET showed significant rises in task-related blood flow activation in three left-hemisphere language regions after 6 weeks with piracetam, against only the left vocalization area with placebo, and the piracetam group gained on 6 language functions against 3 subtests for placebo (Kessler et al., 2000).

A 2016 meta-analysis of 7 randomized trials with 261 people found no significant difference in overall aphasia severity (standardized mean difference 0.23, 95% CI -0.03 to 0.49) but one in written language (0.35, 95% CI 0.04 to 0.66). The effect appeared early and declined, and the authors described a limited role (Zhang et al., 2016). Models: human randomized trials, PET imaging and a meta-analysis.